Like the three other immune checkpoint proteins (PD-1, PD-L1, and CTLA-4), TIGIT expression was also associated with markers of tumor inflammation, including the count of cancer cells within 80 μm of lymphocytes (pan-cancer and BRCA), the total number of lymphocytes in CT + CAS (pan-cancer and BRCA), and the proportional count of lymphocytes to cancer cells within 80 μm of the CSI (LUAD) (Fig. 6bv and Supplementary Fig. 11v). Here, CTLA4 is linked to cancer.